Modulation of cisplatin resistance in acquired-resistant nonsmall cell lung cancer cells

Shinn Liang Lai, Jaulang Hwang, Reury Perng Perng, Jacqueline Whang-Peng

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

To obtain cisplatin (CDDP)-resistant cells possessing the clinically induced resistance phenotype, H-460 nonsmall cell lung cancer cells (NSCLC) were pulse treated with 20, 60, 80 μM CDDP for 1 h every week, respectively. Twelve months later, three CDDP-resistant cell lines (H-460/CDDP20, H460/CDDP60, H-460/CDDP80) were obtained that exhibit different levels of CDDP resistance (6- to 22 fold), and the possible mechanisms of resistance were studied. These resistant cells were cross-resistant to carboplatin and melphalan, but not to adriamycin or 5-fluorouracil. CDDP resistance in these cell lines appeared to be stable even after 6 months of growth in cisplatin-free medium. There was no evidence of drug accumulation differences between parental and resistant cells. Although both intracellular glutathione (GSH) content and glutathione S-transferase (GST) activity increased 1.5- to 2.5-fold in the resistant cells, only a minimal reversal of drug resistance was observed after buthionine sulfoximine (BSO) treatment, which depleted intracellular GSH levels. An enhancement of DNA repair activity was found in the resistant cell lines and played the major role in the cisplatin resistance phenotype. Using H-460/CDDP80 cells as a model, addition of a nontoxic concentration of pentoxifylline (PTX) significantly enhanced CDDPinduced cytotoxicity in a synergistic manner. Furthermore, more prominent reversal of CDDP resistance could be achieved when the resistant cells were pretreated with BSO, followed by PTX and CDDP combined treatment. This provides a rationale for combination therapy in refractory lung cancer using CDDP and two resistance modulators.

Original languageEnglish
Pages (from-to)31-38
Number of pages8
JournalOncology Research
Volume7
Issue number1
Publication statusPublished - 1995
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Cisplatin
Buthionine Sulfoximine
Pentoxifylline
Cell Line
Phenotype
Melphalan
Carboplatin
Glutathione Transferase
Drug Resistance
Fluorouracil
DNA Repair
Doxorubicin
Glutathione
Lung Neoplasms
Growth
Pharmaceutical Preparations

Keywords

  • acquired drug resistance
  • buthionine sulfoximine
  • cisplatin
  • nonsmall cell lung cancer
  • pentoxifylline
  • resistance modulators

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Modulation of cisplatin resistance in acquired-resistant nonsmall cell lung cancer cells. / Lai, Shinn Liang; Hwang, Jaulang; Perng, Reury Perng; Whang-Peng, Jacqueline.

In: Oncology Research, Vol. 7, No. 1, 1995, p. 31-38.

Research output: Contribution to journalArticle

Lai, Shinn Liang ; Hwang, Jaulang ; Perng, Reury Perng ; Whang-Peng, Jacqueline. / Modulation of cisplatin resistance in acquired-resistant nonsmall cell lung cancer cells. In: Oncology Research. 1995 ; Vol. 7, No. 1. pp. 31-38.
@article{20c3edd0d6c44701ab8df6f3c0e3facb,
title = "Modulation of cisplatin resistance in acquired-resistant nonsmall cell lung cancer cells",
abstract = "To obtain cisplatin (CDDP)-resistant cells possessing the clinically induced resistance phenotype, H-460 nonsmall cell lung cancer cells (NSCLC) were pulse treated with 20, 60, 80 μM CDDP for 1 h every week, respectively. Twelve months later, three CDDP-resistant cell lines (H-460/CDDP20, H460/CDDP60, H-460/CDDP80) were obtained that exhibit different levels of CDDP resistance (6- to 22 fold), and the possible mechanisms of resistance were studied. These resistant cells were cross-resistant to carboplatin and melphalan, but not to adriamycin or 5-fluorouracil. CDDP resistance in these cell lines appeared to be stable even after 6 months of growth in cisplatin-free medium. There was no evidence of drug accumulation differences between parental and resistant cells. Although both intracellular glutathione (GSH) content and glutathione S-transferase (GST) activity increased 1.5- to 2.5-fold in the resistant cells, only a minimal reversal of drug resistance was observed after buthionine sulfoximine (BSO) treatment, which depleted intracellular GSH levels. An enhancement of DNA repair activity was found in the resistant cell lines and played the major role in the cisplatin resistance phenotype. Using H-460/CDDP80 cells as a model, addition of a nontoxic concentration of pentoxifylline (PTX) significantly enhanced CDDPinduced cytotoxicity in a synergistic manner. Furthermore, more prominent reversal of CDDP resistance could be achieved when the resistant cells were pretreated with BSO, followed by PTX and CDDP combined treatment. This provides a rationale for combination therapy in refractory lung cancer using CDDP and two resistance modulators.",
keywords = "acquired drug resistance, buthionine sulfoximine, cisplatin, nonsmall cell lung cancer, pentoxifylline, resistance modulators",
author = "Lai, {Shinn Liang} and Jaulang Hwang and Perng, {Reury Perng} and Jacqueline Whang-Peng",
year = "1995",
language = "English",
volume = "7",
pages = "31--38",
journal = "Oncology Research",
issn = "0965-0407",
publisher = "Cognizant Communication Corporation",
number = "1",

}

TY - JOUR

T1 - Modulation of cisplatin resistance in acquired-resistant nonsmall cell lung cancer cells

AU - Lai, Shinn Liang

AU - Hwang, Jaulang

AU - Perng, Reury Perng

AU - Whang-Peng, Jacqueline

PY - 1995

Y1 - 1995

N2 - To obtain cisplatin (CDDP)-resistant cells possessing the clinically induced resistance phenotype, H-460 nonsmall cell lung cancer cells (NSCLC) were pulse treated with 20, 60, 80 μM CDDP for 1 h every week, respectively. Twelve months later, three CDDP-resistant cell lines (H-460/CDDP20, H460/CDDP60, H-460/CDDP80) were obtained that exhibit different levels of CDDP resistance (6- to 22 fold), and the possible mechanisms of resistance were studied. These resistant cells were cross-resistant to carboplatin and melphalan, but not to adriamycin or 5-fluorouracil. CDDP resistance in these cell lines appeared to be stable even after 6 months of growth in cisplatin-free medium. There was no evidence of drug accumulation differences between parental and resistant cells. Although both intracellular glutathione (GSH) content and glutathione S-transferase (GST) activity increased 1.5- to 2.5-fold in the resistant cells, only a minimal reversal of drug resistance was observed after buthionine sulfoximine (BSO) treatment, which depleted intracellular GSH levels. An enhancement of DNA repair activity was found in the resistant cell lines and played the major role in the cisplatin resistance phenotype. Using H-460/CDDP80 cells as a model, addition of a nontoxic concentration of pentoxifylline (PTX) significantly enhanced CDDPinduced cytotoxicity in a synergistic manner. Furthermore, more prominent reversal of CDDP resistance could be achieved when the resistant cells were pretreated with BSO, followed by PTX and CDDP combined treatment. This provides a rationale for combination therapy in refractory lung cancer using CDDP and two resistance modulators.

AB - To obtain cisplatin (CDDP)-resistant cells possessing the clinically induced resistance phenotype, H-460 nonsmall cell lung cancer cells (NSCLC) were pulse treated with 20, 60, 80 μM CDDP for 1 h every week, respectively. Twelve months later, three CDDP-resistant cell lines (H-460/CDDP20, H460/CDDP60, H-460/CDDP80) were obtained that exhibit different levels of CDDP resistance (6- to 22 fold), and the possible mechanisms of resistance were studied. These resistant cells were cross-resistant to carboplatin and melphalan, but not to adriamycin or 5-fluorouracil. CDDP resistance in these cell lines appeared to be stable even after 6 months of growth in cisplatin-free medium. There was no evidence of drug accumulation differences between parental and resistant cells. Although both intracellular glutathione (GSH) content and glutathione S-transferase (GST) activity increased 1.5- to 2.5-fold in the resistant cells, only a minimal reversal of drug resistance was observed after buthionine sulfoximine (BSO) treatment, which depleted intracellular GSH levels. An enhancement of DNA repair activity was found in the resistant cell lines and played the major role in the cisplatin resistance phenotype. Using H-460/CDDP80 cells as a model, addition of a nontoxic concentration of pentoxifylline (PTX) significantly enhanced CDDPinduced cytotoxicity in a synergistic manner. Furthermore, more prominent reversal of CDDP resistance could be achieved when the resistant cells were pretreated with BSO, followed by PTX and CDDP combined treatment. This provides a rationale for combination therapy in refractory lung cancer using CDDP and two resistance modulators.

KW - acquired drug resistance

KW - buthionine sulfoximine

KW - cisplatin

KW - nonsmall cell lung cancer

KW - pentoxifylline

KW - resistance modulators

UR - http://www.scopus.com/inward/record.url?scp=0029067343&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029067343&partnerID=8YFLogxK

M3 - Article

C2 - 7549042

AN - SCOPUS:0029067343

VL - 7

SP - 31

EP - 38

JO - Oncology Research

JF - Oncology Research

SN - 0965-0407

IS - 1

ER -